solifenacin   Click here for help

GtoPdb Ligand ID: 7483

Synonyms: Vesicare® | YM-67905 | YM-905
Approved drug
solifenacin is an approved drug (FDA (2004), UK (2009))
Compound class: Synthetic organic
Comment: The marketed formulation contains solifenacin succinate (PubChem CID 216457).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: solifenacin

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 32.78
Molecular weight 362.2
XLogP 3.57
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(N1CCc2c(C1c1ccccc1)cccc2)OC1CN2CCC1CC2
Isomeric SMILES O=C(N1CCc2c([C@@H]1c1ccccc1)cccc2)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Solifenacin is a competitive cholinergic receptor antagonist. Antagonism of muscarinic acetlycholine receptors (in particular the M2 and M3 subtypes) in the bladder reduces tonus (elastic tension) of the urinary bladder and slows parasympathetic contractions. This relieves the symptoms associated with overactive bladder syndrome by increasing bladder capacity and decreasing urinary urgency.
External links Click here for help